Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

13.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessibility of telomeric overhangs to stabilizing small-molecule ligands.

Nucleic acids research·2026
Same author

Evaluation of correlations between serum and urinary vitamin D metabolites using LC-MS/MS.

Bioscience reports·2026
Same author

Novel macrocyclic peptides as potent and selective inhibitors of human neutrophil serine protease 4.

Journal of molecular biology·2026
Same author

Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblasts.

Nature communications·2026
Same author

Cooperative Chiral Induction in Aromatic <i>N</i>,<i>N</i>'-Dialkylated Urea Organocatalyst Enables Asymmetric Aza-Henry Reaction.

The Journal of organic chemistry·2026
Same author

Flow-mediated endothelial remodeling and inflammation drive developmental vascular susceptibility in ldlr loss of function.

Nature communications·2026
Same journal

IgA is necessary and sufficient to prevent norovirus infection in mice.

Science translational medicine·2026
Same journal

Human donor liver viability evaluation with polarization-sensitive optical coherence tomography.

Science translational medicine·2026
Same journal

<i>Kbtbd13</i> knockdown restores muscle function in a clinically relevant mouse model of nemaline myopathy type 6.

Science translational medicine·2026
Same journal

AI-CURA, an automated LLM workflow for high-accuracy genetic variant classification.

Science translational medicine·2026
Same journal

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

Science translational medicine·2026
Same journal

<i>SPP1</i><sup>hi</sup> macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synovium.

Science translational medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.2K

Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk.

Moshe Shashar1, Mostafa E Belghasem2, Shinobu Matsuura3

  • 1Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.

Science Translational Medicine
|November 24, 2017
PubMed
Summary
This summary is machine-generated.

New research reveals how indolic solutes in chronic kidney disease (CKD) cause hyperthrombosis via the aryl hydrocarbon receptor (AHR) and tissue factor (TF) pathway, mediated by STIP1 homology and U-box-containing protein 1 (STUB1). This offers a way to reduce clotting risks without increasing bleeding.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.2K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.8K

Area of Science:

  • Nephrology
  • Vascular Biology
  • Biochemistry

Background:

  • Chronic kidney disease (CKD) increases atherothrombosis risk and bleeding complications.
  • Mechanisms linking uremic solutes, vascular proteins (tissue factor [TF], aryl hydrocarbon receptor [AHR]), and thrombosis/bleeding risks are unclear.
  • Indolic uremic solutes are implicated in CKD-related vascular dysfunction.

Purpose of the Study:

  • To elucidate the mechanisms by which indolic solutes drive hyperthrombosis in CKD.
  • To investigate the role of the aryl hydrocarbon receptor (AHR) and tissue factor (TF) in this process.
  • To identify potential therapeutic targets for managing thrombotic risks in CKD without affecting hemostasis.

Main Methods:

  • Development of an indolic solute-specific animal model for CKD.
  • Investigation of AHR- and TF-dependent pathways.
  • Analysis of STIP1 homology and U-box-containing protein 1 (STUB1) as a ubiquitin ligase regulating TF.
  • Inhibition of STUB1 in vascular smooth muscle cells and assessment of thrombosis and bleeding in flow loops.
  • Human studies correlating STUB1 and TF expression in uremic vessels.

Main Results:

  • Indolic solutes mediate a hyperthrombotic phenotype in CKD via an AHR- and TF-dependent mechanism.
  • AHR regulates TF through STUB1, a ubiquitin ligase that degrades TF via ubiquitination in the uremic environment.
  • Human uremic vessels show an inverse relationship between STUB1 and TF expression and reduced STUB1-TF interaction.
  • STUB1 manipulation in vascular smooth muscle cells inhibited thrombosis without prolonging bleeding time.
  • STUB1 perturbations reversed the uremic hyperthrombotic phenotype, unlike heparin.

Conclusions:

  • STUB1 acts as a key mediator in the indolic solute-AHR-TF axis, refining the understanding of CKD thrombosis.
  • Targeting STUB1 offers a novel strategy to mitigate hyperthrombosis in CKD without compromising hemostatic balance.
  • This approach presents a promising therapeutic avenue for CKD patients facing both thrombotic and bleeding risks.